These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 18922100)

  • 1. Perspectives in therapy for hepatitis C.
    Vento S; Cainelli F; Temesgen Z
    Expert Opin Investig Drugs; 2008 Nov; 17(11):1635-9. PubMed ID: 18922100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges.
    Li H; Shi ST
    Future Med Chem; 2010 Jan; 2(1):121-41. PubMed ID: 21426049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations.
    Khalid O; Bacon BR
    Clin Liver Dis; 2011 Aug; 15(3):573-83. PubMed ID: 21867937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational drugs for hepatitis C.
    Flisiak R; Parfieniuk A
    Expert Opin Investig Drugs; 2010 Jan; 19(1):63-75. PubMed ID: 20001555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
    Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
    Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boceprevir.
    Rizza SA; Talwani R; Nehra V; Temesgen Z
    Drugs Today (Barc); 2011 Oct; 47(10):743-51. PubMed ID: 22076489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
    Martin MT; Deming P
    Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
    Zeuzem S; Buggisch P; Agarwal K; Marcellin P; Sereni D; Klinker H; Moreno C; Zarski JP; Horsmans Y; Mo H; Arterburn S; Knox S; Oldach D; McHutchison JG; Manns MP; Foster GR
    Hepatology; 2012 Mar; 55(3):749-58. PubMed ID: 22006408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
    Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
    Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of NS3 protease inhibitors in HCV infection.
    Goudreau N; Llinàs-Brunet M
    Expert Opin Investig Drugs; 2005 Sep; 14(9):1129-44. PubMed ID: 16144497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.
    Naggie S; Patel K; McHutchison J
    J Antimicrob Chemother; 2010 Oct; 65(10):2063-9. PubMed ID: 20688770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
    Chen SH; Tan SL
    Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
    Lamers MH; Broekman M; Drenth JP; Gluud C
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD011132. PubMed ID: 24937404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel methods of hepatitis C treatment and prevention].
    Chmielewska AM; Rychłowska M; Król E; Solarz K; Bieńkowska-Szewczyk K
    Postepy Hig Med Dosw (Online); 2015 Aug; 69():946-63. PubMed ID: 26400881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections.
    Venkatraman S
    Trends Pharmacol Sci; 2012 May; 33(5):289-94. PubMed ID: 22521415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.